Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 19, 2007, Pages 5349-5352

  Takeuchi, Kumiko ^a   Holloway, William G ^a   McKinzie, Jamie H ^a   Suter, Todd M ^a   Statnick, Michael A ^a   Surface, Peggy L ^a   Emmerson, Paul J ^a   Thomas, Elizabeth M ^a   Siegel, Miles G ^a   Matt, James E ^a   Wolfe, Chad N ^a   Mitch, Charles H ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Carboxamido biaryl ethers; Obesity; Opioid receptor antagonists (OpRAs)

Indexed keywords

6 [4 (2 BENZYLAMINOETHYL)PHENOXY]NICOTINAMIDE; AMIDE; DELTA OPIATE RECEPTOR; ETHER DERIVATIVE; KAPPA OPIATE RECEPTOR; LY 255582; MU OPIATE RECEPTOR; NALTREXONE; OPIATE ANTAGONIST; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ARTICLE; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; STRUCTURE ACTIVITY RELATION;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DESIGN; ETHERS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; MOLECULAR CONFORMATION; RECEPTORS, OPIOID; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34548596549     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.08.008     Document Type: Article

References (13)

1. Stein C.J., and Colditz G.A. J. Clin. Endocrinol. Metab. 89 (2004) 2522
2. Reid L.D. Am. J. Clin. Nutr. 42 (1985) 1099
3. Glass M.J., Billington C.J., and Levine A.S. Neuropeptides 33 (1999) 360
4. Margules D.L., Moisset B., Lewis M.J., Shibuya H., and Pert C.B. Science 202 (1978) 988
5. Welch C.C., Kim E.M., Grace M.K., Billington C.J., and Levine A.S. Brain Res. 721 (1996) 126
6. Mandenoff A., Fumeron F., Apfelbaum M., and Margules D.L. Science 215 (1982) 1536
7. Glass M.J., Grace M., Cleary J.P., Billington C.J., and Levine A.S. Am. J. Physiol. 271 (1996) R217
8. Yeomans M.R., and Gray R.W. Neurosci. Biobehav. Rev. 26 (2002) 713
9. Mitch C.H., Leander J.D., Mendelsohn L.G., Shaw W.N., Wong D.T., Cantrell B.E., Johnson B.G., Reel J.K., Snoddy J.D., Takemori A.E., and Zimmerman D.M. J. Med. Chem. 36 (1993) 2842
10. Statnick M.A., Tinsley F.C., Eastwood B.J., Suter T.M., Mitch C.H., and Heiman M.L. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284 (2003) R1399
11. 3H]-bremazocine binding) opioid receptors expressed in CHO cells under high sodium conditions (n ≥ 2). Under low sodium binding conditions the affinity was reduced at the receptor subtypes, consistent with findings on the prototype Lilly 4-phenylpiperidine opioid antagonist series: see. Emmerson P.J., McKinzie J.H., Surface P., Suter T.M., Mitch C.H., and Statnick M.A. Eur. J. Pharmacol. 494 (2004) 121
12. In vitro functional assay, inhibiting agonist stimulated G-protein activation (measured using GTPγS binding) in CHO membranes expressing the cloned human mu, kappa, and delta receptors (n ≥ 2). In the present study, opioid ligand binding and GTPγS functional assays were converted to a homogeneous SPA permitting the development of simpler assays with dramatically increased throughput. Optimization in the presence of sodium chloride was designed to bias these assays toward the detection of opioid antagonists: see. Rodgers G., Hubert C., McKinzie J., Suter T., Statnick M., Emmerson P., and Stancato L. Assay Drug Dev. Technol. 1 (2003) 627
13. 5-Fluoro-2-pyridinecarboxamide was prepared from 2-amino-5-fluoropyridine via Sandmeyer reaction followed by ester/amide formation or direct amidation of 2-bromo-5-fluoropyridine, the Sandmeyer product, with CuCN in DMF.